CAJ | 학술논문

目的:在蛋白及基因水平检测乳腺癌中HER-2的表达,比较免疫组化(IHC)及荧光原位杂交(FISH)法检测结果,分析其临床应用.方法: 应用免疫组化及荧光原位杂交法测定HER-2蛋白表达及基因扩增.结果: IHC检测HER-2蛋白,77例乳腺浸润性导管癌中 ,[(-)-(+)]占 35.06%,(++)占37.66%,(+++)占27.27%;FISH检测HER-2基因,扩增阳性率为51.95%.IHC强阳性组(+++),FISH阳性率为90.48%,IHC弱阳性组(++), FISH阳性率为 68.97%,IHC阴性组[(-)-(+)], FISH阳性率为 3.07%,P<0.01,具有显著统计学意义.以HER-2基因扩增为阳性标准,IHC 结果(+++)阳性预测值为90.48%,灵敏度为95.00%,特异度为92.86%;(++)阳性预测值为68.97%,灵敏度为95.24%,特异度为74.29%;[(-)-(+)]阴性预测值为96.30%.结论:HER-2蛋白过表达主要是基因扩增所致,IHC强阳性 (+++)及IHC阴性[(-)-(+)] 可直接指导临床用药,IHC弱阳性(++)需行FISH确定有无基因扩增.
목적:재단백급기인수평검측유선암중HER-2적표체,비교면역조화(IHC)급형광원위잡교(FISH)법검측결과,분석기림상응용.방법: 응용면역조화급형광원위잡교법측정HER-2단백표체급기인확증.결과: IHC검측HER-2단백,77례유선침윤성도관암중 ,[(-)-(+)]점 35.06%,(++)점37.66%,(+++)점27.27%;FISH검측HER-2기인,확증양성솔위51.95%.IHC강양성조(+++),FISH양성솔위90.48%,IHC약양성조(++), FISH양성솔위 68.97%,IHC음성조[(-)-(+)], FISH양성솔위 3.07%,P<0.01,구유현저통계학의의.이HER-2기인확증위양성표준,IHC 결과(+++)양성예측치위90.48%,령민도위95.00%,특이도위92.86%;(++)양성예측치위68.97%,령민도위95.24%,특이도위74.29%;[(-)-(+)]음성예측치위96.30%.결론:HER-2단백과표체주요시기인확증소치,IHC강양성 (+++)급IHC음성[(-)-(+)] 가직접지도림상용약,IHC약양성(++)수행FISH학정유무기인확증.